Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦42Â÷ KSTH Ãá°èÇмú´ëȸ : 2023-05-12
±³À°ÀÏÀÚ : 2023-05-12
±³À°Àå¼Ò : ¼¿ï°¡µçÈ£ÅÚ 2F ±×·£µåº¼·ëȦ
±³À°ÁÖÁ¦ : Á¦42Â÷ KSTH Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 02-790-2426
À̸ÞÀÏ : ksth@thrombo.or.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, ÀÀ±ÞÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á¹ý, ÀÇ·á°æ¿µ, ±âŸ
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í ±âŸ 10,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 05¿ù 12ÀÏ È¦A 08:50~09:00 °³È¸»ç ()
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 09:00~09:25 Immune TTP : new therapeutic options and their optimal use ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 09:00~09:25 Future of factor XI inhibitors for arterial thromboembolism ½Åµ¿È£(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 09:25~09:50 TTP : Management following recovery from an acute episode and during remission ¾È¼¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 09:25~09:50 Anticoagulation strategy in older patients with Atrial fibrillation ½ÉÀç¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 09:50~10:15 Complement of secondary TMA : pathophysiology and treatment È«ÁؽÄ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 09:50~10:15 Atrial fibrillation in acute myocardial infarction À§Áø(°¡ÃµÀÇ´ë)
Åä·Ð 05¿ù 12ÀÏ È¦A 10:15~10:30 Discussion ±èÁø¼®,±è¼ºÇö(¿¬¼¼ÀÇ´ë, µ¿¾ÆÀÇ´ë)
Åä·Ð 05¿ù 12ÀÏ È¦B 10:15~10:30 Discussion ¾È¿µ±Ù, ³ª»óÈÆ(Àü³²ÀÇ´ë, ¼¿ïÀÇ´ë)
ÈÞ½Ä 05¿ù 12ÀÏ 10:30~10:45 coffee break ()
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 10:45~11:10 How to differentiate tumor thrombus or bland thrombus ³ª»óÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 10:45~11:10 Antiplatelet therapy in patients with thrombocytopenia or anemia Çã¾Ö¿µ(°¿øÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 11:10~11:35 An update on risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses ȲÇå±Ô(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 11:10~11:35 Catheter-related arterial thrombosis & bleeding Á¶ÀÎÁ¤(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 11:35~12:00 Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia ±è°æÇÏ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 11:35~12:00 Heparin-induced thrombocytopenia °¹Î°æ(ÇѸ²ÀÇ´ë)
Åä·Ð 05¿ù 12ÀÏ È¦A 12:00~12:15 Discussion ±è¾ç±â,ÃÖ¿øÀÏ(¼øõÇâÀÇ´ë, ¸íÁöº´¿ø)
Åä·Ð 05¿ù 12ÀÏ È¦B 12:00~12:15 Discussion Á¤¸íÈ£,À强¼ö(Àü³²ÀÇ´ë,¿ï»êÀÇ´ë)
½Ä»ç 05¿ù 12ÀÏ 12:15~13:15 Lunch ()
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 13:15~13:40 Emicizumab : lab issue ¹Ú»óÇõ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 13:15~13:40 Recent advances of immune thrombocytopenia Á¤Çظ²(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 13:40~14:05 vonwillebrand disease - Áø´Ü, ºÐ·ù, NGS ±è³²Èñ(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 13:40~14:05 Magement of thrombocytopenia associated with autoimmune disease Çö½Å¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 14:05~14:30 Rare bleeding disorders (VWD Á¦¿Ü, rare factor deficiency) (FVII, FXI deficiency) Çѽ¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 14:05~14:30 Coagulopathy and Thrombocytopenia in liver disease Àü¹ÎÁö(°í·ÁÀÇ´ë)
Åä·Ð 05¿ù 12ÀÏ È¦A 14:30~14:45 Discussion À¯Ã¶¿ì,À¯Ã¶ÁÖ(À»ÁöÀÇ´ë, ¿¬¼¼ÀÇ´ë)
Åä·Ð 05¿ù 12ÀÏ È¦B 14:30~14:45 Discussion À±¼º¼ö,¹®¿µÃ¶(¼¿ïÀÇ´ë, ÀÌÈÀÇ´ë)
ÈÞ½Ä 05¿ù 12ÀÏ 14:45~15:00 coffee break ()
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 15:00~15:25 New approaches to chemotherapy-induced thrombocytopenia ¹Ú¿µÈÆ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 15:00~15:25 An Insight into Recent Advances on Platelet Function in Health and Disease ±è¼öÁ¾(ÃæºÏ´ë ¼öÀÇÇаú)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 15:25~15:50 Antiplatelet and anticoagulant therapy during the CIT period ÃÖ°¿î(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 15:25~15:50 P-and E-selectin in venous thrombosis and non-venous pathologies ¹Ú¼³Èñ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 15:50~16:15 Recurrence and bleeding complication of cancer-associated thrombosis ÀÌÁöÀ±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦B 15:50~16:15 Endothelial dysfunction in COVID-19 ±èº¸Çö(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ È¦A 16:15~16:40 cancer-associated thrombosis management in patients with preexisting cardiovascular disease ±èÀº°æ(¼º±Õ°üÀÇ´ë)
Åä·Ð 05¿ù 12ÀÏ È¦B 16:15~16:30 Discussion ¹Ú³ëÁø,¼ÛÀç¿ì(¼øõÇâÀÇ´ë,¿¬¼¼ÀÇ´ë)
Åä·Ð 05¿ù 12ÀÏ È¦A 16:40~16:50 panel discussion ½ÉÁö¿µ,Á¤¿ì¹é,ÀÓÈ£¿µ,ȲÇå±Ô(¿¬¼¼ÀÇ´ë, Ä«Å縯ÀÇ´ë,ÀüºÏÀÇ´ë,¼øõÇâÀÇ´ë)
±âŸ 05¿ù 12ÀÏ È¦A 16:50~16:55 Æóȸ½Ä ()